William Dager, Pharm.D., BCPS (AQ-Cardiology)

wedager@ucdavis.edu

Current Title(s):

  • Pharmacist Specialist, UC Davis Medical Center
  • Clinical Professor of Medicine, UC Davis School of Medicine
  • Clinical Professor of Pharmacy, Touro University College of Pharmacy

At UC Davis Medical Center since: 1985

Program Director since: 2009

Education:

  • Pharm.D., UC San Francisco School of Pharmacy, 1985
  • General Pharmacy Residency, UC Davis Medical Center, 1986
  • Nephrology Pharmaceutical Care Preceptorship, University of Pittsburgh, 1995

Professional Biography

Bill is a board-certified pharmacotherapy specialist with added qualifications in cardiology. He is a clinical specialist at UC Davis Medical Center, where his practice focus is cardiology, cardiovascular surgery and anticoagulation.  He is also involved in pharmacokinetics and management of selected critical care-related situations and mentors residents in nephrology and non-malignant hematology.  He is the director of the PGY-2 residency in cardiology. He currently holds three adjunct academic recognitions as a full professor, and one of 6 pharmacists recognized as a Master in Critical Care Medicine (MCCM).

Bill is a recipient of multiple teaching and mentoring awards, including the ACCP Best Practice award in 2008, the Long teaching award from UCSF and the outstanding mentor award from the ACCP Cardiology PRN. He is a reviewer and/or editorial board member for multiple medical journals, including chair of the Editorial Advisory Board panel on anticoagulation for the Annals of Pharmacotherapy. He is the co-chair for the Society of Critical Care Medicine 2019 Congress and currently serves as a Reagent for the American College of Critical Care Medicine.

Bill has authored approximately 100 peer reviewed articles, over 30 book chapters, and is a co-editor of the ASHP Anticoagulation Therapy Point of Care guide with the second edition published in 2018. He is an active lecturer, both nationally and internationally, and has research interests involving anticoagulation, critical care, cardiovascular disease, and pharmacokinetics/pharmacodynamics.

Selected Publications

Trask A, Gosselin RC, Diaz J, Dager WE. Warfarin initiation and monitoring with clotting factors II, VII and X levels.  The Annals of Pharmacotherapy 2004;38:251-6.

Chan A, Dager WE. Systemic anticoagulant prophylaxis for central catheter associated venous thrombosis in cancer patients. The Annals of Pharmacotherapy 2007;41:635-41.

Heintz BH, Matzke GR, Dager WE.  Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis. Pharmacotherapy 2009;29:562-77.

Nagle E, Tsu L, Dager WE. Bivalirudin for Anticoagulation during Hypothermic Cardiopulmonary Bypass and Recombinant Factor VIIa for Iatrogenic Coagulopathy. The Annals of Pharmacotherapy 2011;45:e47

Tsu L, Dager WE.  Bivalirudin dosing patterns for renal function including presence of hemodialysis in the management of heparin induced thrombocytopenia. The Annals of Pharmacotherapy 2011;45:1185-92

Heintz BH, Thompson III GR, Dager WE. Clinical Experience with Aminoglycosides in Dialysis-Dependent Patients: Risk Factors for Mortality and Reassessment of Current Dosing Practices. The Annals of Pharmacotherapy 2011;45:1338-45

Tsu LV, Dager WE. Comparison of bivalirudin dosing strategies using total, adjusted, and ideal body weights in obese patients with heparin-induced thrombocytopenia. Pharmacotherapy. 2012;32:20-6.

Tsu LV, Dienes JE, Dager WE. Vitamin K Dosing to Reverse Warfarin Based on INR, Route of Administration, and Home Warfarin Dose in the Acute/Critical Care Setting. Ann Pharmacother. 2012;46:1617-26.

Nagle EL, Dager WE, Duby JJ, Roberts AJ, Kenny LE, Murthy MS, Pretzlaff RK. Bivalirudin in pediatric patients maintained on extracorporeal life support. Pediatr Crit Care Med. 2013;14:e182-8.

Tsu LV, Dager WE. Safety of new oral anticoagulants with dual antiplatelet therapy in patients with acute coronary syndromes. Ann Pharmacother. 2013 Apr;47:573-7.

Pon TK, Dager WE, Roberts AJ, White RH. Subcutaneous enoxaparin for therapeutic anticoagulation in hemodialysis patients. Thromb Res. 2014;133:1023-8.

Dager W, Tsu L, Pon T. Considerations for Systemic Anticoagulation in ESRD. Semin Dial. 2015;28:354-62.

Chen LD, Roberts AJ, Dager WE. Safety and efficacy of starting warfarin after two consecutive platelet count rises in heparin-induced thrombocytopenia. Thromb Res. 2016;144:229-33.

Dager WE, Lee JA. Filtering Out Use of DOACs in Hemodialysis. Ann Pharmacother. 2017;51:511-513.

Steele AP, Lee JA, Dager WE. Incomplete dabigatran reversal with idarucizumab. Clin Toxicol (Phila). 2018;56:216-218.

Walker EA, Dager WE. Bridging with Tirofiban during Oral Antiplatelet Interruption: A Single-Center Case Series Analysis Including Patients on Hemodialysis. Pharmacotherapy. 2017;37:888-892.

Walker EA, Roberts AJ, Louie EL, Dager WE. Bivalirudin Dosing Requirements in Adult Patients on Extracorporeal Life Support with or without Continuous Renal Replacement Therapy. ASAIO J. 2018 Published on line